Johnson & Johnson (NYSE:JNJ) Shares Sold by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. lessened its stake in Johnson & Johnson (NYSE:JNJ) by 79.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 510,936 shares of the company’s stock after selling 1,992,838 shares during the period. Mawer Investment Management Ltd.’s holdings in Johnson & Johnson were worth $73,892,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. IFS Advisors LLC raised its stake in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $32,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $38,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on JNJ shares. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Stifel Nicolaus decreased their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Bank of America raised their price objective on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. Finally, Raymond James lowered their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $171.33.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 0.3 %

Shares of JNJ stock opened at $163.63 on Friday. The company has a market capitalization of $394.32 billion, a price-to-earnings ratio of 24.61, a PEG ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average price of $158.68 and a 200 day moving average price of $156.13. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.29 earnings per share. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.03%. Johnson & Johnson’s payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.